Status message

Not the entire site translated, but only to "Journal"

Algorithm for the Treatment of Primary Negative Symptoms in Schizophrenia

Moscow Research Institute of Psychiatry – a branch of the FSBI “National Medical Research Center for Psychiatry and Addiction named after V.P. Serbian” Ministry of Health of Russian Federation, Moscow, Russia

Abstract: This article provides a brief overview of relevant literature data (systematic reviews, meta-analysis), as well as the treatment algorithm of primary dominant negative symptoms in schizophrenia, based on evidences from randomized controlled trials. Psychopharmacotherapy of primary negative symptoms is described in detail, including the group of drugs used, the first-choice therapy, the next steps in case of its inefficiency, and possible methods of treatment of resistant cases.
Contact: profmosolov@mail.ru

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat or click here to download the PDF file.

References: 

1.    Galderisi S., Bucci P., Mucci A. et al. Categorical and dimensional approaches to negative symptoms of schizophrenia: focus on long-term stability and functional outcome // Schizophr Res. – 2013. – Vol. 147, No. 1. – P. 157–162. 
2.    Kirkpatrick B. Developing Concepts in Negative Symptoms: Primary vs Secondary and Apathy vs Expression // J Clin Psychiatry. – 2014. – Vol. 75. – P. 3–7.
3.    Strauss G.P., Horan W.P., Kirkpatrick B. et al. Deconstructing negative symptoms of schizophrenia: Avolition–apathy and diminished expression clusters predict clinical presentation and functional outcome // J Psychiatr Res. – 2013. – Vol. 47. – P. 783–790.
4.    Millan M.J., Andrieux A., Bartzokis G. et al. Altering the course of schizophrenia: progress and perspectives // Nat Rev Drug Discov. – 2016. – Vol. 15. – P. 485–515.
5.    Mosolov S.N., Yaltonskaya P.A. Razvitie kontseptsii, klassifikatsiya i klinicheskaya differentsiatsiya negativnykh simptomov pri shizofrenii // Sovremennaya terapiya psikhicheskikh rasstroistv. – 2020. – № 1. – S. 2–15.
6.     Riedel M., Muller N., Strassnig M. et al. Quetiapine has equivalent efficacy and superior tolerability to risperidone in the treatment of schizophrenia with predominantly negative symptoms // Eur Arch Psychiatry. – 2005. – Vol. 255, No. 6 . – P. 432-437.
7.    Mucci A., Merlotti E., Üçok A. et al. Primary and persistent negative symptoms: Concepts, assessments and neurobiological bases // Schizophr Res. – 2017. – Vol. 186. – P. 19–28.
8.    Tandon R. Antipsychotics in the treatment of schizophrenia: an overview // J Clin Psychiatry. – 2011. – Vol. 72. – P. 4–8.
9.     Solmi M., Murru A., Pacchiarotti I. et al. Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review // Ther Clin Risk Manag. – 2017. – Vol. 13. – P. 757–777.
10.    Leucht S., Corves C., Arbter D et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis // Lancet. – 2009. – Vol. 373. – P. 31–41.
11.    Huhn M., Nikolakopoulou A., Schneider-Thoma J. et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis // Lancet. – 2019. – Vol. 14, No. 394. – P. 939–951.
12.    Leucht S. Amisulpride a selective dopamine antagonist and atypical antipsychotic: results of a meta-analysis of randomized controlled trials // Int J Neuropsychopharmacol. – 2004. – Vol. 7, No. 1. – P. 15–S20. 
13.    Kumar S., Chaudhury S. Efficacy of amisulpride and olanzapine for negative symptoms and cognitive impairments: an open-label clinical study // Ind Psychiatry J. – 2014. – Vol. 23, No. 1. – P. 27–35.
14.     Levine S.Z., Leucht S. Treatment response heterogeneity in the predominant negative symptoms of schizophrenia: analysis of amisulpride vs placebo in three clinical trials // Schizophr Res. – 2014. – Vol. 156, No. 1. – P. 107–114.
15.    Möller H.J. Amisulpride: efficacy in the management of chronic patients with predominant negative symptoms of schizophrenia // Eur Arch Psychiatry Clin Neurosci. – 2001. – Vol. 251, No. 5. – P. 217–224.
16.    Krause M., Zhu Y., Huhn M. et al. Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis // Eur Arch Psychiatry Clin Neurosci. – 2018. – Vol. 268, No. 7. – P. 625–639.
17.    Boyer P., Lecrubier Y., Puech A.J. et al. Treatment of negative symptoms in schizophrenia with amisulpride // Br J Psychiatry. – 1991. – Vol. 166, No. 1. – P. 68–72.
18.    Danion J.M., Rein W., Fleurot O. Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride // Am J Psychiatry. – 1999. – Vol. 156, No. 4. – P. 610–616. 
19.    Loo H., Poirier-Littre M.F., Theron M. et al. Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia // Br J Psychiatry. – 1997. – Vol. 170. – P. 18–22.
20.    Lecrubier Y., Quintin P., Bouhassira M. et al. The treatment of negative symptoms and deficit states of chronic schizophrenia: Olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial // Acta Psychiatr Scand. – 2006. – Vol. 114, No. 5. – P. 319–327.
21.    Pani L., Gessa G. The substituted benzamides and their clinical potential on dysthymia and on the negative symptoms of schizophrenia // Mol Psychiatry. – 2002. – Vol. 7. – P. 247–253.
22.    Saletu B., Küfferle B., Grünberger J. et al. Clinical, EEG mapping and psychometric studies in negative schizophrenia: Comparative trials with amisulpride and fluphenazine // Neuropsychobiology. – 1994. – Vol. 29, No. 3. – P. 125–135.
23.    Speller J.C., Barnes T.R., Curson D.A. et al. One-year, low-dose neuroleptic study of in-patients with chronic schizophrenia characterised by persistent negative symptoms. Amisulpride v. haloperidol // Br J Psychiatry. – 1997. – Vol. 171. – P. 564–568.
24.    Olié J.P., Spina E., Murray S. et al. Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: Results of a 12-week, double-blind study // Int Clin Psychopharmacol. – 2006. – Vol. 21, No. 3. – P. 143–151.
25.    Fusar-Poli P., Papanastasiou E., Stahl D. et al. Treatments of negative symptoms in schizophrenia: meta-analysis of 168 randomized placebo-controlled trials // Schizophr Bull. – 2015. – Vol. 41, No. 4. – P. 892–899.
26.    Leucht S., Arbter D., Engel R.R., Kissling W., Davis J.M. et al. How effective are second-generation antipsychotic drugs? A metaanalysis of placebo-controlled trials // Mol Psychiatry. – 2009. – Vol. 14, No. 4. – P. 429–447.
27.    Leucht S., Komossa K., Rummel-Kluge C. et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia // Am J Psychiatry. – 2009. – Vol. 166, No. 2. – P. 152–163.
28.    Németh G., Laszlovszky I., Czobor P. et al. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial // Lancet. – 2017. – Vol. 389, No. 10074. – P. 1103–1113.
29.    Németh B., Molnár A., Akehurst R. et al. Quality-adjusted life year difference in patients with predominant negative symptoms of schizophrenia treated with cariprazine and risperidone // J Comp Eff Res. – 2017. – Vol. 6, No. 8. – P. 639–648.
30.    Buchanan R.W., Panagides J., Zhao J. et al. Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia // J Clin Psychopharmacol. – 2012. – Vol. 32, No. 1. – P. 36–45.
31.    Lindenmayer J.P., Khan A., Iskander A. et al. A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia // J Clin Psychiatry. – 2007. – Vol. 68, No. 3. – P. 368–379. 
32.    Kinon B.J., Noordsy D.L., Liu-Seifert H., Gulliver A.H., Ascher-Svanum H., Kollack-Walker S. Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning // J Clin Psychopharmacol. – 2006. – Vol. 26, No. 5. – P. 453–461. 
33.    Sirota P., Pannet I., Koren A., Tchernichovsky E. Quetiapine versus olanzapine for the treatment of negative symptoms in patients with schizophrenia // Hum Psychopharmacol. – 2006. – Vol. 21, No. 4. – P. 227–234. 
34.    Alvarez E., Ciudad A., Olivares J.M., Bousoño M., Gómez J.C. A randomized, 1-year follow-up study of olanzapine and risperidone in the treatment of negative symptoms in outpatients with schizophrenia // J Clin Psychopharmacol. – 2006. – Vol. 26, No. 3. – P. 238–249.
35.    Ciudad A., Olivares J.M., Bousoño M., Gómez J.C., Alvarez E. Improvement in social functioning in outpatients with schizophrenia with prominent negative symptoms treated with olanzapine or risperidone in a 1 year randomized, open-label trial // Prog Neuropsychopharmacol Biol Psychiatry. – 2006. – Vol. 30, No. 8. – P. 1515–1522. 
36.    Mosolov S.N., Kapiletti S.G., Zhigareva N.P.Dlitel'naya terapiya sertindolom bol'nykh shizofreniei s preobladaniem negativnoi simptomatiki // Sovremennaya terapiya psikhicheskikh rasstroistv. – 2011. – T. 2. – C. 17–26.
37.    Riedel M., Muller N., Strassnig M., et al. Quetiapine has equivalent efficacy and superior tolerability to risperidone in the treatment of schizophrenia with predominantly negative symptoms // Eur Arch Psychiatry Clin Neurosci. – 2005. – Vol. 255, No. 6. – P. 432–437. 
38.    Correll C.U., Rubio J.M., Inczedy-Farkas G., Birnbaum M.L., Kane J.M., Leucht S. Efficacy of 42 Pharmacologic Cotreatment Strategies Added to Antipsychotic Monotherapy in Schizophrenia: Systematic Overview and Quality Appraisal of the Meta-analytic Evidence // JAMA Psychiatry. – 2017. – Vol. 74, No. 7. – P. 675–684.
39.    Galling B., Roldán A., Hagi K. et al. Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis // World Psychiatry. – 2017. – Vol. 16, No. 1. – P. 77–89.
40.    Galling B., Vernon J.A., Pagsberg A.K., Wadhwa A., Grudnikoff E., Seidman A.J., Tsoy-Podosenin M., Poyurovsky M., Kane J.M., Correll C.U. Efficacy and safety of antidepressant augmentation of continued antipsychotic treatment in patients with schizophrenia // Acta Psychiatr Scand. – 2018. – Vol. 137, No. 3. – P. 187–205.
41.    Zheng W., Xiang Y.-T., Xiang Y.-Q. et al. Efficacy and safety of adjunctive topiramate for schizophrenia: a meta-analysis of randomized controlled trials // Acta Psychiatr Scand. – 2016. – Vol. 134, No. 5. – P. 385–398.
42.    Kishi T., Mukai T., Matsuda Y., Iwata N. Selective serotonin 3 receptor antagonist treatment for schizophrenia: meta-analysis and systematic review // Neuromolecular Med. – 2014. – Vol. 16, No. 1. – P. 61–69.
43.    Premkumar T.S., Pick J. Lamotrigine for schizophrenia // Cochrane Database Syst Rev. – 2006. – Vol. 18, No. 4. – CD005962.
44.    Andrade C., Kisely S., Monteiro I., Rao S. Antipsychotic augmentation with modafinil or armodafinil for negative symptoms of schizophrenia: systematic review and meta-analysis of randomized controlled trials // J Psychiatr Res. – 2015. – Vol. 60. – P. 14–21.
45.    Solmi M., Veronese N., Thapa N., et al. Systematic review and meta-analysis of the efficacy and safety of minocycline in schizophrenia // CNS Spectr. – 2017. – Vol. 22, No. 5. – P. 415–426.
46.    Heringa S.M., Begemann M.J.H., Goverde A.J., Sommer I.E.C.. Sex hormones and oxytocin augmentation strategies in schizophrenia: A quantitative review // Schizophr Res. – 2015. – Vol. 168, No. 3. – P. 603–613.
47.    Singh J., Kour K., Jayaram M.B. Acetylcholinesterase inhibitors for schizophrenia // Cochrane Database Syst Rev. – 2012. – Vol. 1. – CD007967.
48.    Silver H., Nassar A. Fluvoxamine improves negative symptoms in treated chronic schizophrenia: an add-on double-blind, placebo-controlled study // Biol Psychiatry. – 1992. – Vol. 31. – P. 698–704.
49.    Spina E., De Domenico P., Ruello C. et al. Adjunctive fluoxetine in the treatment of negative symptoms in chronic schizophrenic patients // Int Clin Psychopharmacol. – 1994. – Vol. 9. – P. 281–285.
50.    Goff D.C., Midha K.K., Sarid-Segal O. et al. A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia // Psychopharmacology. – 1995. – Vol. 117. – P. 417–423.
51.    Salokangas R.K., Saarijärvi S., Taiminen T. et al. Citalopram as an adjuvant in chronic schizophrenia: A double-blind placebo-controlled study // Acta Psychiatr Scand. – 1996. – Vol. 94. – P. 175–180.
52.    Taiminen TJ, Syvälahti E, Saarijärvi S, et al. Citalopram as an adjuvant in schizophrenia: further evidence for a serotonergic dimension in schizophrenia // Int Clin Psychopharmacol. – 1997. – Vol. 12. – P. 31–35.
53.    Jockers-Scherübl M.C., Bauer A., Godemann F. et al. Negative symptoms of schizophrenia are improved by the addition of paroxetine to neuroleptics // Int Clin Psychopharmacol. – 2005. – Vol. 20. – P. 27–31. 
54.    Helfer B., Samara M.T., Huhn M. et al. Efficacy and safety of antidepressants added to antipsychotics for schizophrenia: a systematic review and meta-analysis // Am J Psychiatry. – 2016. – Vol. 173, No. 9. – P. 876–886. 
55.    Singh S.P., Singh V., Kar N. et al. Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis // Br J Psychiatry. – 2010. – Vol. 197, No. 3. – P. 174–179. 
56.    Chang J.S., Ahn Y.M., Park H.J.et al. Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial // J Clin Psychiatry. – 2008. – Vol. 369, No. 5. – P. 720–731.
57.    Muscatello M.R.A., Bruno A., Pandolfo G. et al. Effect of aripiprazole augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study // Schizophr Res. – 2011 – Vol. 127. – P. 93-99.
58.    Arango C., Garibaldi G., Marder S.R. Pharmacological approaches to treating negative symptoms: A review of clinical trials // Schizophr Res. – 2013 – Vol. 150. – P. 346–352.
59.    Deakin B., Suckling J., Barnes T.R.E. et al. The benefit of minocycline on negative symptoms of schizophrenia in patients with recent-onset psychosis (BeneMin): a randomised, double-blind, placebo-controlled trial // Lancet Psychiatry. – 2018. – Vol. 5, No. 11. – P. 885–894. 
60.    Aleman A., Lincoln T.M., Bruggeman R. et al. Treatment of negative symptoms: where do we stand, and where do we go? // Schizophr Res. – 2016. – Vol. 186. – P. 55–62.
61.    Dlabac-de Lange J., Knegtering R., Aleman A. Repetitive transcranial magnetic stimulation for negative symptoms of schizophrenia: review and meta-analysis // J Clin Psychiatry. – 2010. – Vol. 71. – P. 411–418.
62.    Wobrock T. Guse B., Cordes J. et al. Left prefrontal high-frequency rTMS for the treatment of schizophrenia with predominant negative symptoms: a sham-controlled, randomized multicentre trial // Biol Psychiatry. − 2015. − Vol. 77, No. 11. − P. 979–988.
63.    Aleman A., Enriquez-Geppert S., Knegtering H. et al. Moderate effects of noninvasive brain stimulation of the frontal cortex for improving negative symptoms in schizophrenia: Meta-analysis of controlled trials // Neurosci Biobehav Rev. − 2018. − Vol. 89. − P. 111–118. 
64.    Hawkins E.L., Hawkins R.D., Dennis M. et al. Animal-assisted therapy for schizophrenia and related disorders: A systematic review // J Psychiatr Res. − 2019. − Vol. 115. − P. 51–60. 
65.    Cai C., Yu L., Rong L. et al. Effectiveness of humor intervention for patients with schizophrenia: A randomized controlled trial // J Psychiatr Res. − 2014. − Vol. 59, No. 3. − P. 174–178.
66.    Dauwan M., Begemann M.J., Heringa S.M. et al. Exercise Improves Clinical Symptoms, Quality of Life, Global Functioning, and Depression in Schizophrenia: A Systematic Review and Meta-analysis // Schizophr Bull. − 2016. − Vol. 42, No. 3. − P. 588–599. 
67.    Maurus I., Hasan A., Röh A. et al. Neurobiological effects of aerobic exercise, with a focus on patients with schizophrenia // Eur Arch Psychiatry Clin Neurosci. − 2019. − Vol. 269, No. 5. − P. 499–515. 
68.    Lutgens D., Gariepy G., Malla A. Psychological and psychosocial interventions for negative symptoms in psychosis: systematic review and meta-analysis // Br J Psychiatry. − 2017. − Vol. 210, No. 5. − P. 324–332.
69.    Klingberg S., Wölwer W., Engel C. et al. Negative Symptoms of Schizophrenia as Primary Target of Cognitive Behavioral Therapy: Results of the Randomized Clinical TONES Study // Schizophr Bull. − 2011. − Vol. 37. − P. 98–100.
70.    Cella M., Wykes T. The nuts and bolts of Cognitive Remediation: Exploring how different training components relate to cognitive and functional gains // Schizophr Res. − 2019. − Vol. 203. − P. 12–16.
71.    Bandelow B., Zohar J., Kasper S. et al. How to grade categories of evidence // World J Biol Psychiatry. − 2008. − Vol. 9, No. 4. − P. 242–247.
72.    Nasrallah H.A., Cucchiaro J.B., Mao Y. et al. Lurasidone for the treatment of depressive symptoms in schizophrenia: analysis of 4 pooled, 6-week, placebo-controlled studies // CNS Spectr. − 2015. − Vol. 20, No. 2. − P. 140−147.
73.    Siris S.G. Depression in schizophrenia: perspective in the era of “Atypical” antipsychotic agents // Am J Psychiatry. − 2000. − Vol. 157, No. 9. − P. 1379–1389.
74.    Siris S.G. Suicide and schizophrenia // J Psychopharmacol. − 2001. − Vol. 15, No. 2. − P. 127 – 135.
75.    Hasan A., Falkai P., Wobrock T. et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia. Part 3: Update 2015 Management of special circumstances: Depression, Suicidality, substance use disorders and pregnancy and lactation // World J Biol Psychiatry. − 2015. − Vol. 16, No. 3. − P. 142−170.
76.    Luan S., Wan H., Wang S., Li H., Zhang B. Efficacy and safety of olanzapine/fluoxetine combination in the treatment of treatment-resistant depression: a meta-analysis of randomized controlled trials // Neuropsychiatr Dis Treat. − 2017. − Vol. 13. − P. 609−620.
77.    Figueiredo T., Segenreich D., Mattos P. Fluoxetine Adjunctive Therapy for Obsessive-Compulsive Symptoms Associated With Olanzapine in Schizophrenic Patients // Journal of Clinical Psychopharmacology. − 2016. − Vol. 36, No. 4. − P. 389–391.
78.    Hasan A., Falkai P., Wobrock T. et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia. Part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance // World J Biol Psychiatry. − 2012. − Vol. 13, No. 5. − P. 318–378.
79.    Mosolov S.N. Osnovy psikhofarmakoterapii. M.: Vostok, 1996. − 242 s.
80.    Mosolov S.N. Klinicheskoe primenenie sovremennykh antidepressantov. SPb.: Meditsinskoe informatsionnoe agentstvo, 1995. – 568 s.
81.    Dilsaver S.C., Coffman J.A. Cholinergic hypothesis of depression: a reappraisal // J Clin Psychopharmacol. − 1989. − Vol. 9. − P. 173–179.
82.    Bermanzohn P.C., Siris S.G. Akinesia: a syndrome common to parkinsonism, retarded depression, and negative symptoms of schizophrenia // Compr Psychiatry. − 1992. − Vol. 33, No. 4. − P. 221−232.
83.    Bischof M., Kaiser S. Negativsymptome – Diagnostik und Therapie // InFo Neurol Psychiatr. – 2016. – Vol. 14.
84.    Kirkpatrick B., Strauss G.P., Nguyen L. et al. The brief negative symptom scale: psychometric properties // Schizophr Bull. − 2011. − Vol. 37, No. 2. − P. 300–305. 
85.    Mucci A., Vignapiano A., Bitter I. et al. A large European, multicenter, multinational validation study of the Brief Negative Symptom Scale // Eur Neuropsychopharmacol. – 2019 – Vol. 29, No. 8. – P. 947–959.
86.    Kay S.R., Fiszbein A., Opler L.A. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia // Schizophr Bull. – 1987. – Vol. 13, No. 2. – P. 261–276.
87.    Ivanova E., Khan A., Liharska L. et al. Validation of the Russian Version of the Positive and Negative Syndrome Scale (PANSS-Ru) and Normative Data // Innov Clin Neurosci. – 2018. – Vol. 15, No. 9. – P. 32–48.
88.    Addington D., Addington J., Schissel B. A depression rating scale for schizophrenics // Schizophr Res. – 1990. – Vol. 3, No. 4. – P. 247–251.
89.    Hawley C.J., Finberg N., Roberts A.G. et al. The use of the Simpson Angus Scale for the assessment of movement disorder: training guide // International Journal of Psychiatry in Clinical Practice. − 2003. − Vol. 7. − P. 249–257.
90.    Lako I.M., Bruggeman R., Knegtering H. et al. A systematic review of instruments to measure depressive symptoms in patients with schizophrenia // J Affect Disord. − 2012. − Vol. 140, No. 1. − P. 38−47.